Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Neurogen Biomarking LLC · NCT07701161
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–90 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 1000
- US sites recruiting
- 1
- Study start
- January 13, 2025
- Record last updated
- July 14, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Conditions: Alzheimer s Disease; MCI Conversion to Dementia; pTau217; Biomarkers
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
Exclusion Criteria
- Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Recruiting US locations
Insigth Hospital and Medical Center Chicago
Chicago, IL 60616
Site contact: Ansam Eghzawi, MD · +18109410076 · ansam@neurogenbiomarking.com
Study contacts (from the official record)
- Ansam Eghzawi, MD · +18109410076 · ansam@neurogenbiomarking.com
- Elisabeth Thijssen, PhD · +16282788161 · elisabeth@neurogenbiomarking.com
Similar studies in Illinois
All neurology studies in Illinois →- RecruitingHealthy volunteersEarly Phase 1
Effect of Neural Constraints on Movement in Stroke
Northwestern University
- Location
- Chicago, IL
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersEarly Phase 1
R01.Aim 2.Study 1: IsoReach
Shirley Ryan AbilityLab
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteers
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment…
GAP Innovations, PBC
- Location
- Chicago, IL + 18 other US sites
- Eligibility basics
- Ages 60–90
- RecruitingHealthy volunteersPhase 3
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma, LLC
- Location
- Evanston, IL
- Eligibility basics
- Ages 45+